A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
Sponsor: GlaxoSmithKline
This PHASE1/PHASE2 trial investigates Lung Adenocarcinoma and Lung Cancer and is currently completed. GlaxoSmithKline leads this study, which shows 13 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2024 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2023 — May 2024 [monthly]
Completed PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1_PHASE2
▶ Show 8 earlier versions
-
Mar 2022 — Dec 2022 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Mar 2022 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jul 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Aug 2019 — Jul 2020 [monthly]
Recruiting PHASE1_PHASE2
-
May 2019 — Aug 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2018 — May 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Mar 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- Memorial Sloan Kettering Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .